Skin patch to continuously delivery levodopa treat Parkinson’s disease is underway.
The new skin patch developed by NeuroDerm is designed to maintain concentration of the anti-Parkinson’s medication levodop in a continuous manner for improving the treatment outcome.
Levodopa is currently the most effective drug for Parkinson’s disease.
The experimental levodopa patch code-named ND0611 increases levodopa bioavailability and extends its effects by administering a novel pharmaceutical.
Studies in animals using the levodapa patch found that it modified levodopa’s efficacy by increasing levodopa plasma half-life and activity period.
The patch also helped in maintaining levodopa plasma concentrations in a typical therapeutic range besides extending dopaminergic stimulation in the brain.
Levodopa patch’s mode of action involves an under-exploited levodopa metabolic pathway and has the potential for markedly improving clinical benefits from levodopa.
This Phase 1 study was conducted in healthy volunteers with the purpose of measuring the safety and tolerability of ND0611 at different doses.
Further analysis will be completed to determine the pharmacokinetic profile of levodopa in plasma.
The company expects to present the results of this phase 1 study in the second half of 2010.
“The completion of this first step in the clinical development of ND0611 marks an important milestone in the path to develop a new therapeutic alternative for Parkinson’s disease patients,” stated Oded S. Lieberman, PhD, NeuroDerm’s chairman and CEO.
While constant levodopa plasma concentrations achieved through continuous levodopa infusion have been shown to bring significant benefit to Parkinson’s patients, these options are generally impractical.
In contrast, ND0611 may offer a new treatment alternative that can be widely adopted for chronic control of the most common problems affecting Parkinson’s disease.
NeuroDerm is an emerging pharmaceutical company that develops therapeutic dermal patches for the treatment of CNS diseases.
NeuroDerm’s technology is based on proprietary reformulations of well established oral drugs whose low bio-availability is the major impediment to better efficacy. Besides ND0611, NeuroDerm is developing ADD, ADHD, schizophrenia and Alzheimer’s disease. NeuroDerm is headquartered in the Weizmann Science Park, Ness Ziona, Israel.
Parkinson’s disease is a progressive disorder of the nervous system that affects movement. It develops gradually, often starting with a barely noticeable tremor in just one hand.
The symptoms of Parkinson’s disease can vary from person to person. Tremor, slowed motion, rigid muscles, impaired posture and balance, loss of automatic movements, speech changes, dementia are some of the most common symptoms.
Levodopa is the most effective Parkinson’s drug, which is a natural substance in the body. When taken by mouth in pill form, it passes into the brain and is converted to dopamine.
- Neuroplasticity Can Prevent Alzheimer’s According To This Study
- GE Healthcare to Form Coalition Targeting Neurodegenerative Diseases : Press Releases : News : GE
- Virtual reality-based exercises to aid Parkinson’s disease patients
- What predicts mortality in Parkinson disease?
- Application for iPhone may help monitor Parkinson’s disease
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- March 2009
- November 2008
- October 2008
- September 2008
- July 2008
- May 2008